The HSPBP1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population targeting human HSPBP1 within the A-549 lung adenocarcinoma cell line. This loss-of-function model is generated via CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool that avoids clonal artifacts. The product is supplied as a frozen vial of early-passage polyclonal cells, ready for functional studies of HSPBP1 in cancer biology, proteostasis, and stress responses.
The parental A-549 line was established from a 58-year-old Caucasian male with lung adenocarcinoma. These epithelial cells are extensively used to investigate drug metabolism, epithelial barrier dynamics, and chemoresistance mechanisms. Their stable genetic background provides a reliable platform for CRISPR-based gene editing, enabling dissection of HSPBP1 function specifically within the lung adenocarcinoma epithelial microenvironment.
HSPBP1 encodes a co-chaperone that binds the ATPase domain of HSP70 chaperones (HSPA1A, HSPA8), inhibiting their ATPase and substrate refolding activities. This interaction is a pivotal regulatory point in the proteostasis network. HSPBP1 expression is induced by heat shock and oxidative stress via HSF1 and post-transcriptionally repressed by miR-125b. Downstream, it modulates BAG3-mediated autophagy and folding of client proteins such as kinases and steroid receptors, while suppressing apoptosis through Bcl-2 family members. HSPBP1 physically interacts with the co-chaperone BAG2 and the ubiquitin ligase CHIP (STUB1), which directs HSP70 substrates to the proteasome. Thus, HSPBP1 integrates stress signals to govern cell survival and death decisions.
In A-549 cells, HSPBP1 is frequently overexpressed and linked to anti-apoptotic traits that promote chemoresistance. The polyclonal knockout population allows systematic interrogation of HSPBP1 dependency in cell survival, proliferation, and drug response. Disruption of HSPBP1 disinhibits HSP70, potentially rebalancing proteostasis and sensitizing cells to stress-induced apoptosis. This model is therefore valuable for evaluating HSPBP1?CHSP70 interface targeting as a therapeutic strategy and for studying chaperone network influences on epithelial homeostasis and drug transporter function.
Key applications include western blotting, RT-qPCR, co-immunoprecipitation of HSP70 complexes, Annexin V/PI apoptosis assays, proteasome activity measurements, and chemosensitivity assays with cisplatin or bortezomib. Migration/invasion assays assess metastatic potential. The polyclonal design supports population-based genomic and proteomic analyses. Additional applications include neurodegenerative disease and ischemia-reperfusion injury research. For further details, please contact Ascent Research.
